INS and Hypoglycemia: For our in vivo observations, the hypoglycemia observed in chronic taurine administration may be attributed to activation of insulin release via transport into the β-cells, inhibition of glucagon release via interaction of taurine with the GABAA receptors on the α-cells, or a combination of these events.